Triple antiviral therapy with telaprevir after liver transplantation: a case series

References

• Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680–687.
   PubMed Web of Science ®Google Scholar
• Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14(Suppl 2):36–44.
   Google Scholar
• Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274–287.
   PubMed Web of Science ®Google Scholar
• Wang CS, Ko HH, Yoshida EM, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6(7):1586–1599.
   Web of Science ®Google Scholar
• Xirouchakis E, Triantos C, Manousou P, et al. Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15(10):699–709.
   Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peg-interferon alpha-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicenter phase 2 trial. Lancet. 2011;376:705–716.
   Google Scholar
• Jacobson IM, McHutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
   PubMed Web of Science ®Google Scholar
• Jacobson I, Foster GR, Fried MW, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol. 2013;58:574.
   Google Scholar
• Manns M, Poordad F, Alfonso de Araujo ES. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol. 2013;58:568.
   Web of Science ®Google Scholar
• Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26(4):531–548.
   Web of Science ®Google Scholar
• Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55(5):1620–1628.
   PubMed Web of Science ®Google Scholar
• Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int. 2013;33(Suppl 1):56–62.
   Google Scholar
• Coilly A, Furlan V, Roche B, et al. Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence. Antimicrob Agents Chemother. 2012;56(11):5728–5734.
   Web of Science ®Google Scholar
• Coilly A, Roche B, Botta-Fridlund D, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol. 2012;56:21.
   Web of Science ®Google Scholar
• Coilly A, Roche B, Dumontier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol. 2014;60(1):78–86.
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013;19(7):690–700.
   Web of Science ®Google Scholar
• Kim B, Trivedi A, Thung SN, Grewal P. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis. 2014;34(1):108–112.
   Web of Science ®Google Scholar
• Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13(6):1601–1605.
   PubMed Web of Science ®Google Scholar
• Forns X, Prieto M, Charlton M, et al. Sofosbuvir compassionate use program for patients with severe reccurent hepatitis c including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol. 2014;60:26.
   Web of Science ®Google Scholar
• Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53(1):317–324.
   PubMed Web of Science ®Google Scholar
• Tempestilli M, D’Offizi G, Lionetti R, et al. Increased plasma concentration of Ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir. Hepatology. In press 2013.
   Google Scholar
• D’Avolio A, Pensi D, Baietto L, Di Perri G. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. In press 2014.
   Google Scholar
• Farnik H, Zimmermann T, Herrmann E, et al. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver Int. In press 2014.
   Google Scholar
• Calista D, Landi G. Lichen planus, erythema nodosum, and erythema multiforme in patient with chronic hepatitis C. Cutis. 2001;67(6):454–456.
   Web of Science ®Google Scholar
• Ionescu C, Micu L, Constantinescu I, et al. Prolonged Treatment with Interferon Alpha and Peginterferon Induces Rheumatoid Arthritis Syndrome and Erythema Nodosum. J Gastrointestin Liver Dis. 2008;17(2):211–212.
   Web of Science ®Google Scholar